We are live on ! Find out more
OKUR

OnKure Therapeutics
OKUR

51 hedge funds and large institutions have $114M invested in OnKure Therapeutics in 2026 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

256% more capital invested

Capital invested by funds: $32M → $114M (+$82M)

115.31% more ownership

Funds ownership: 85.96% → 201.27% (+115%)

100% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 9

16% more funds holding

Funds holding: 44 → 51 (+7)

14% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 14

Holders
51
Holders Change
+7
Holders Change %
+15.91%
% of All Funds
0.63%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.02%
New
18
Increased
12
Reduced
14
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
RCM
RA Capital Management
Massachusetts
+$12.3M
2
SG
StepStone Group
California
+$6.7M
3
BI
BVF Inc
California
+$6.11M
4
VC
Vivo Capital
California
+$5.95M
5
FCMV
Foresite Capital Management VI
California
+$4.46M

Top Sellers

1
SC
Shay Capital
New York
-$2M
2
HCM
Highbridge Capital Management
New York
-$1.57M
3
CF
Cantor Fitzgerald
New York
-$1.07M
4
RA
Rosalind Advisors
Ontario, Canada
-$885K
5
Citadel Advisors
Citadel Advisors
Florida
-$573K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
26
BlackRock
New York
$205K -$9.54K -3,091 -6%
NA
27
NewEdge Advisors
Louisiana
$184K +$138K +44,551 New
VFT
28
Vanguard Fiduciary Trust
Pennsylvania
$180K +$134K +43,371 New
AC
29
Aldebaran Capital
Indiana
$167K -$2.67K -865 -2%
Citadel Advisors
30
Citadel Advisors
Florida
$156K -$573K -185,538 -83%
HF
31
HRT Financial
New York
$153K +$114K +37,055 New
Marshall Wace
32
Marshall Wace
United Kingdom
$151K +$113K +36,444 New
XT
33
XTX Topco
Cayman Islands
$141K +$50.4K +16,328 +92%
Millennium Management
34
Millennium Management
New York
$126K +$94.2K +30,499 New
Jane Street
35
Jane Street
New York
$111K +$22.8K +7,398 +38%
Barclays
36
Barclays
United Kingdom
$104K -$6.92K -2,242 -8%
Two Sigma Investments
37
Two Sigma Investments
New York
$100K +$40K +12,942 +114%
GCP
38
GSA Capital Partners
United Kingdom
$92K -$73.2K -23,724 -52%
Northern Trust
39
Northern Trust
Illinois
$82.4K – – –
BCM
40
Bridgeway Capital Management
Texas
$67.5K -$9.9K -3,207 -16%
Morgan Stanley
41
Morgan Stanley
New York
$59.3K -$32.8K -10,635 -43%
Wells Fargo
42
Wells Fargo
California
$55.9K +$7.72K +2,500 +23%
State Street
43
State Street
Massachusetts
$55.7K +$41.6K +13,462 New
UBS Group
44
UBS Group
Switzerland
$14.1K +$6.75K +2,187 +181%
VGA
45
Vanguard Global Advisers
Pennsylvania
$3.08K +$2.3K +745 New
BNP Paribas Financial Markets
46
BNP Paribas Financial Markets
France
$1.16K – – –
Royal Bank of Canada
47
Royal Bank of Canada
Ontario, Canada
$1K +$395 +128 +125%
TCOT
48
Trust Company of Toledo
Ohio
$563 – – –
Osaic Holdings
49
Osaic Holdings
Arizona
$372 -$59 -19 -17%
JP Morgan Chase
50
JP Morgan Chase
New York
$171 -$1.54K -500 -92%
1
2
3

OKUR Hedge Fund Activity: Q1 2026 in Review

51 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q1 2026, worth a combined $114M — up 256% from $32M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new OKUR positions and 9 closed out — a net gain of 9 holders — while 12 added to existing stakes and 14 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $12.3M. The largest seller was Shay Capital, cutting an estimated $2M.

  • 51 institutional investors held OnKure Therapeutics (OKUR) as of Q1 2026, up from 44 in Q4 2025.
  • Funds reported $114M of OnKure Therapeutics stock for Q1 2026, up 256% quarter-over-quarter.
  • 18 funds opened new OnKure Therapeutics positions in Q1 2026 and 9 closed out, a net change of +9 holders.
  • The largest OnKure Therapeutics buyer in Q1 2026 was RA Capital Management, an estimated $12.3M added.
  • The largest OnKure Therapeutics seller in Q1 2026 was Shay Capital, an estimated $2M sold.

Based on aggregated 13F filings for Q1 2026.